Medicxi Ventures to launch as independent VC firm

2 February 2016

Medicxi Ventures on Tuesday announced the close of Medicxi Ventures 1 (MV1), a new 210 million euro ($250 million) fund that will focus on early-stage life sciences investments.

The venture capital firm said MV1 will predominantly invest in Europe. Pharma major GlaxoSmithKline (LSE: GSK) and Johnson & Johnson Innovation have invested in MV1, the company said in a statement. Collaboration with pharmaceutical companies will continue to be a key strategy helping the firm to deliver on this mission, it added.

Dr Moncef Slaoui, chairman global vaccines and GSK’s representative on Medicxi’s Scientific Advisory Board, said: "We are delighted to support the Medicxi team and this early stage investment fund. We believe in the potential to create an exciting pipeline of new medicine candidates by collaborating and investing with an asset-centric model. The team at Medicxi has a proven track record in partnering with world-class entrepreneurs and scientists to translate disruptive science from academia and industry into new medicines with demonstrable patient benefits.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK